Samumed wins orphan drug status for inhaled IPF therapy

Samumed said today that the FDA awarded orphan drug status to its inhaled idiopathic pulmonary fibrosis therapy, SMo4646.

The IPF therapy is administered using a nebulizer and can be used as a montherapy or in combination with pirfenidone or nintedanib, according to the San Diego-based company.

Get the full story at our sister site, Drug Delivery Business News.

The post Samumed wins orphan drug status for inhaled IPF therapy appeared first on MassDevice.

from MassDevice http://ift.tt/2tv9jvD